Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lidocaine transdermal patch - Immune Pharmaceuticals Inc

Drug Profile

Lidocaine transdermal patch - Immune Pharmaceuticals Inc

Alternative Names: ADL 87223; LidoPAIN BP; LidoPAIN HM; LidoPAIN SP; LidoPAIN TV

Latest Information Update: 23 May 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator EpiCept Corporation
  • Developer EpiCept Corporation; Immune Pharmaceuticals Inc
  • Class Acetanilides; Class Ib antiarrhythmics; Local anaesthetics; Non-opioid analgesics; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Back pain
  • Discontinued Headache; Postoperative pain; Tinnitus

Most Recent Events

  • 19 Jan 2018 No recent reports on development identified - Phase-II for Back pain in USA (Transdermal)
  • 31 Dec 2017 Immune Pharmaceuticals has patent protection for lidocaine transdermal patch in USA and Mexico
  • 31 Dec 2017 Immune Pharmaceuticals has patent pending for lidocaine transdermal patch in Mexico
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top